Taken together, our results support the notion that calcitriol suppresses both PI3K/AKT and MAPK/ERK pathways in HER2-positive breast cancer cells, thereby reinforcing its potential as an adjuvant agent in combinatorial therapeutic strategies aimed at improving treatment outcomes and overcoming resistance. Here, ERBB2 is linked to breast carcinoma.